<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To report a case of cytomegalovirus (CMV) endotheliitis after insertion of an intravitreal fluocinolone acetonide (Retisert) implant </plain></SENT>
<SENT sid="1" pm="."><plain>Design: Interventional case report </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Retrospective chart review </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A 40-year-old man received a Retisert implant in the left eye for recurrent <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Although <z:mp ids='MP_0001845'>inflammation</z:mp> became quiescent within a month, corneal <z:hpo ids='HP_0000969'>edema</z:hpo> developed 4 months after insertion </plain></SENT>
<SENT sid="5" pm="."><plain>Polymerase chain reaction analysis for aqueous humor detected 3.9 × 10(4) copies/mL of CMV DNA </plain></SENT>
<SENT sid="6" pm="."><plain>After treatment with oral valganciclovir, CMV DNA nearly disappeared but visual outcome was poor due to <z:e sem="disease" ids="C0948284" disease_type="Disease or Syndrome" abbrv="">corneal decompensation</z:e> resulting from severe endothelial cell loss </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: After Retisert implant, clinicians should be attentive to the potential risk of CMV endotheliitis </plain></SENT>
</text></document>